We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-3.36%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$5.73B
AUM Growth
-$1.02B
Cap. Flow
-$157M
Cap. Flow %
-2.73%
Top 10 Hldgs %
44.42%
Holding
91
New
5
Increased
15
Reduced
36
Closed
16
Avg Time Held
1.8 years
Top 10 Avg Time Held
1.9 years
Top 20 Avg Time Held
1.4 years

Top Buys

Rank Stock Value
1
ABSI icon
Absci
ABSI
+$156M
2
IVVD icon
Invivyd
IVVD
+$121M
3
LIVN icon
LivaNova
LIVN
+$88.7M
4
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
+$44.8M
5
STVN icon
Stevanato
STVN
+$28M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$98.4M
2
ZY
Zymergen Inc. Common Stock
ZY
+$60.9M
3
SLQT icon
SelectQuote
SLQT
+$46.5M
4
CRL icon
Charles River Laboratories
CRL
+$40.1M
5
CI icon
Cigna
CI
+$37.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.61%
2 Consumer Staples 3.39%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
RCEL icon
51
Avita Medical
RCEL
$403M
$23.9M 0.42%
1,346,217
-64,900
-5% -$1.22M
2020 Q3
4 quarters
AMED icon
52
DELISTED
Amedisys
AMED
$22.4M 0.39%
150,376
+17,918
+14% +$3.72M
2019 Q2
9 quarters
BVS icon
53
Bioventus
BVS
$908M
$21.1M 0.37%
1,489,856
+2,900
+0.2% +$44.6K
2021 Q1
2 quarters
KLRS icon
54
Kalaris Therapeutics
KLRS
$47.6M
$21M 0.37%
36,387
-32,487
-47% -$15M
2020 Q3
4 quarters
SNTI icon
55
Senti Biosciences Holdings
SNTI
$7M
$19.1M 0.33%
192,490
-8,800
-4% -$867K
2021 Q2
1 quarter
TKNO icon
56
Alpha Teknova
TKNO
$380M
$18M 0.31%
725,000
– –
2021 Q2
1 quarter
LFST icon
57
Lifestance Health
LFST
$4.46B
$17.7M 0.31%
1,222,408
-34,659
-3% -$667K
2021 Q2
1 quarter
LVTX icon
58
DELISTED
LAVA Therapeutics
LVTX
$16.7M 0.29%
2,816,196
– –
2021 Q1
2 quarters
ACHL
59
DELISTED
Achilles Therapeutics
ACHL
$16.3M 0.28%
2,088,089
– –
2021 Q1
2 quarters
ZGNX
60
DELISTED
Zogenix, Inc.
ZGNX
$15.4M 0.27%
+1,014,414
New +$15.8M
2021 Q3
0 quarters
ONEM
61
DELISTED
1Life Healthcare
ONEM
$12.2M 0.21%
600,432
-1,066,531
-64% -$27.4M
2020 Q1
6 quarters
PROF icon
62
Profound Medical
PROF
$220M
$11.5M 0.2%
787,346
– –
2020 Q1
6 quarters
HOOK icon
63
DELISTED
HOOKIPA Pharma
HOOK
$10.9M 0.19%
184,431
-1,190
-0.6% -$86.3K
2019 Q2
9 quarters
STXS icon
64
Stereotaxis
STXS
$101M
$9.98M 0.17%
1,855,504
– –
2019 Q3
8 quarters
CTSO icon
65
Cytosorbents Corp
CTSO
$13M
$8.48M 0.15%
52,222
-12,996
-20% -$2.11M
2020 Q3
4 quarters
CABA icon
66
Cabaletta Bio
CABA
$239M
$8.47M 0.15%
696,377
-1
-0% -$9
2019 Q4
7 quarters
ITMR
67
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
$8M 0.14%
264,600
-590,300
-69% -$13.1M
2020 Q1
6 quarters
AYLA
68
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
$7.57M 0.13%
667,816
– –
2020 Q2
5 quarters
BCEL
69
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$7.29M 0.13%
1,170,006
-1,290,262
-52% -$8.6M
2019 Q2
9 quarters
APRE icon
70
Aprea Therapeutics
APRE
$7.36M
$3.55M 0.06%
34,746
– –
2019 Q4
7 quarters
XERS icon
71
Xeris Biopharma Holdings
XERS
$1.88B
$3.33M 0.06%
1,358,825
– –
2018 Q2
13 quarters
KA icon
72
DELISTED
Kineta, Inc. Common Stock
KA
$614K 0.01%
8,498
– –
2020 Q4
3 quarters
TCDA
73
DELISTED
Tricida, Inc. Common Stock
TCDA
$254K ﹤0.01%
54,758
– –
2018 Q2
13 quarters
SYRS icon
74
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$174K ﹤0.01%
3,891
– –
2016 Q2
21 quarters
OVID icon
75
Ovid Therapeutics
OVID
$420M
$137K ﹤0.01%
40,674
– –
2017 Q2
17 quarters
1 2
3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return
TIA
Tandem Investment Advisors Charleston, South Carolina $1.49B AUM 12.33% 1-Year Est. Return

Redmile Group's Q3 2021 Portfolio in Review

As of Q3 2021, Redmile Group held 91 positions worth $5.73B, down 15% from $6.76B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Redmile Group's Q3 2021 filing shows 5 new, 15 increased, 36 reduced and 16 closed positions. Its largest new stake was Absci: 8,031,094 shares worth $93.4M. The largest sale was DexCom, an estimated $98.4M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Consumer Staples and Financials.

  • Redmile Group's largest Q3 2021 buy was Absci: 8,031,094 shares worth $93.4M.
  • Redmile Group added most to LivaNova in Q3 2021, an estimated $88.7M increase.
  • Redmile Group's biggest Q3 2021 reduction was Seagen Inc. Common Stock, cutting an estimated $28.6M.
  • Redmile Group fully exited DexCom in Q3 2021, selling an estimated $98.4M.
  • Redmile Group's ten largest holdings make up 44% of its $5.73B portfolio in Q3 2021.
  • Redmile Group opened 5 new positions and closed 16 in Q3 2021.
  • Redmile Group's portfolio value fell 15% quarter-over-quarter to $5.73B.

Based on Redmile Group's 13F filing for Q3 2021, filed 15 Nov 2021.